Activation by interferon-\(\gamma\) of expression of ICAM-1 and MHC class II antigens in tumour cells from colorectal carcinomas

I Donnellan, J Cantrill, I Fraser, A Morris

Abstract

**Aims**—To determine whether lack of MHC class II antigen and intercellular adhesion molecule-1 (ICAM-1) expression in some tumours is due to the inability of the tumour cells to respond to the cytokine interferon-\(\gamma\) (IFN-\(\gamma\)), an important activator of these surface molecules.

**Methods**—Cells from 40 colorectal tumours which did not constitutively express class II MHC antigens or ICAM-1 were kept in short term culture after disaggregation for a few days to two weeks without significant loss of viability. These were treated with IFN-\(\gamma\). Expression of class II MHC antigens and ICAM-1 was determined using immunohistological techniques.

**Results**—There was clear induction in vitro of both MHC class II antigens and ICAM-1 in cells from eight of the tumours, with between 50 and 80% of the tumour cells in the cultures staining positively. The staining was apparent within 24 hours, appeared maximal at about three days, and declined thereafter. There were no obvious differences in cell morphology or viability between the cultures which were inducible and those which were not, nor were there obvious differences between the tumours from which they were derived.

**Conclusions**—Expression of MHC class II antigens and ICAM-1 may be induced by IFN-\(\gamma\) in a small proportion of colorectal tumours which do not constitutively express these antigens, showing that only a minority of tumours are capable of responding to this cytokine.

(J Clin Pathol: Mol Pathol 1995;48:M40–M45)

Keywords: MHC class II antigens, ICAM-1, interferon-\(\gamma\), colorectal tumours.

There is accumulating evidence that tumours can express antigens which are recognised specifically in the context of major histocompatibility complex (MHC) antigens by T lymphocytes. The strongest evidence comes from the study of melanoma, where target antigens and MHC restriction elements have been identified.\(^1\)\(^2\) Evidence for other tumours is less strong but indications are that renal cell carcinomas,\(^3\) lung carcinomas\(^4\) and colorectal carcinomas,\(^5\)\(^6\) amongst others, express tumour antigens which are recognised specifically by T lymphocytes.

T lymphocyte recognition of tumour neo-antigens requires that these be complexed to MHC antigens in so-called MHC restricted recognition.\(^7\) An alternative non-MHC restricted pathway exists which relies on cell adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), a ligand for lymphocyte function associated antigen-1 (LFA-1).\(^8\)\(^9\) ICAM-1 is also necessary for efficient binding of T cells to targets of MHC restricted effector cells.\(^7\)\(^11\)\(^12\)

Tumour cells lacking these molecules at their surfaces will not be recognised by T lymphocytes and so a potentially immunogenic tumour could avoid surveillance. Direct experimental evidence for this has been obtained from a number of mouse models.\(^13\)\(^14\)

Loss of class I MHC antigens (HLA A, B, C), normally expressed by bowel epithelium, is common in colorectal carcinoma, with either single alleles or occasionally all alleles missing.\(^15\)\(^16\)\(^17\) This loss of class I MHC antigen expression by human tumours has been taken as indirect evidence for antitumour mechanisms mediated by specific T lymphocytes as the loss implies immune selection of class I negative cells. However, class II antigens (HLA DR, DP, DQ), not normally expressed by epithelium are expressed by malignant colonic epithelium with about one third of tumours.\(^15\)\(^16\)\(^18\)\(^19\) As with class II antigens, ICAM-1 is not expressed on normal bowel epithelium but is reported to be variably expressed by malignant colonic epithelium.\(^20\)

Both MHC class II antigens and ICAM-1 are overexpressed in areas of inflammation, in autoimmune disease and allograft rejection. In rejecting kidneys, for example, there is increased expression of both MHC class II antigens and ICAM-1 by tubular cells as well as endothelial cells, accompanied by heavy infiltration of activated leucocytes.\(^21\) Cytokines, especially interferon-\(\gamma\) (IFN-\(\gamma\)), which are the products of inflammatory cells, induce or augment the expression of both MHC class II antigens and ICAM-1.\(^22\)\(^23\) The likely mechanism for activation of MHC class II antigens and ICAM-1 in inflammatory conditions is local production of cytokines and this is assumed to be the case for tumours also. However, many colorectal carcinomas fail to express MHC class II antigens and ICAM-1, despite the presence of inflammatory cells. There are two possible explanations for this: either there is insufficient local production of cytokines or the malignant cells are incapable of responding to cytokines. We undertook this study to address the latter possibility.
Activation of ICAM-1 and MHC class II antigens by IFN-γ

At least some colorectal tumour cell lines are able to express both MHC class II antigens and ICAM-1, but results with long term lines are suspect because such lines are selected for in vitro growth and so may not be representative of the original tumour. Also, they are released from the influence of stromal factors, such as inhibitory cytokines, which might prevent expression in vivo. We have therefore treated tumour cells, derived from human colorectal tumours negative for expression MHC class II antigens and ICAM-1, in short term culture with IFN-γ to determine whether they can be induced to express MHC class II antigens and ICAM-1.

Methods
TUMOUR SPECIMENS AND CELL CULTURE
Fresh samples of tumour tissue, macroscopically normal colon and samples of colon affected by ulcerative colitis, were obtained from patients undergoing surgical resection. In the patients with cancer the “macroscopically normal” colon was obtained from a site at least 10 cm from the tumour. Six samples were obtained during colectomy for severe ulcerative colitis. All the specimens were washed individually in sterile RPMI 1640 medium (Gibco BRL Life Technologies, Paisley, UK) before being placed on ice in complete medium (RPMI 1640 supplemented with 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, 2.5 mg/ml gentamicin, and 10% fetal calf serum. A portion of each specimen was snap-frozen in liquid nitrogen and stored at -70°C until immediately prior to sectioning. Sequential 6 μm thick sections of normal and diseased tissue were cut and placed on the same slide, fixed in cold acetone for 10 minutes, air-dried and stored at -70°C until staining. The remaining tumour was washed several times in RPMI 1640 and any debris carefully removed. It was minced into 1 mm² pieces and enzymatically disaggregated in a solution of complete medium supplemented with 0.01 mg/ml hyaluronidase type V, 0.02 mg/ml DNase type I, and 1 mg/ml collagenase type IV (Boeringer-Mannheim, Lewes, UK) for 12 to 15 hours at room temperature. The cells were washed three times by centrifugation in complete medium and then cultured in complete medium at 37°C in 5% CO₂ enriched air. Cultures were supplemented with 100 U/ml recombinant human IFN-γ, 10 μM/ml retinoic acid (Sigma Chemical Co., Poole, UK), or 10 μg/ml recombinant human tumour necrosis factor-α (TNF-α) (R&D Systems Europe, Abingdon, UK): control cultures were not supplemented. Cell viability was assessed daily using the trypan blue exclusion test. Only cultures with >65% viability and no microbial contamination were studied. The medium in the tissue cultures was changed twice weekly. Cytospin slide preparations (Shandon Corporation, Runcorn, UK) of the tumour cell preparations were made after 24, 48 and 72 hours of incubation. Care was taken to ensure that only cells in suspension were taken in order to reduce the likelihood of harvesting fibroblasts which could not be totally eliminated from such short term culture preparations. The slides were air-dried, fixed in cold acetone and stored as described previously.

IMMUNOHISTOCHEMICAL STAINING
The sections and cytospin preparations of cultured cells were stained using an avidin-biotin technique. The slides were permitted to warm to room temperature. Endogenous peroxidase activity was quenched by immersion in 3% hydrogen peroxide in methanol solution for five minutes. The slides were rinsed in phosphate buffered saline (PBS)(pH 7.4) before incubation with the primary antibody (all murine monoclonal antibodies).

These were antibody to ICAM-1 (CD25) clone 84H10 (Serotec MCA532, Oxford, UK); three antibodies recognising human class II framework determinants, clone WR18 recognising determinants common to HLA DR, DP, and DQ (Serotec MCA532), clone CR3/43 recognising a DR specific determinant (Dako, High Wycombe, UK, M775) and L243 also recognising a DR specific determinant (Becton Dickinson, Oxford, UK, 347360); antibody recognising a framework determinant of human HLA A, B, C clone W6/32 (Dako M736); ant carcinoembryonic antigen (CEA) clone 11-7 (Dako M70702); anticytokeratin clone MNF116 (Dako M821); anti-CD3 clone T3-4B5 (Dako M716); and anti-interleukin-2 receptor (CD25) clone ACT-1 (Dako M731).

The sections were rinsed and the secondary biotinylated rabbit antimouse antibody (Dako) added. Incubation with the ABC solution (Dako) followed, and the final chromagen was DAB (3,3’ diaminobenzidine tetrachloride; BDH, Lutterworth, UK). The slides were counter-stained with Meyer’s haematoxylin (BDH), before mounting in DPX (BDH). Frozen sections of human tonsil were used as positive controls throughout the staining procedures: for negative controls, the primary antibody was omitted. Histological confirmation and staging of tumours were carried out on paraffin wax sections stained with haematoxylin and eosin. All slides were assessed by the investigators and reported by experienced histopathologists (Dr J Crocker, Heartlands NHS Trust Hospital and Drs T Ashworth and K Chen, Walsgrave NHS Trust Hospital).

Results
TISSUE SAMPLES
Carcinoma was histologically confirmed in all 50 cases. Of these, six were well differentiated, 38 moderately differentiated, six poorly differentiated, and two of a mucinous type. In six cases the tumour was known to have metastasised to the liver at the time of surgery, in three the tumour was confined to the mucosa (Dukes’ stage A), in 20 it had extended through the bowel wall (Dukes’ stage B), and in 21 adjacent lymph nodes contained tumour deposits (Dukes’ stage C). In six of the 50 cases there was evidence of a pronounced lympho-
Figure 1  Tumour cells were treated and stained after two days of culture.  
A: Control cells (untreated) stained for class II antigen; B: control cells (untreated) stained for ICAM-1; C: IFN-γ treated cells stained for class II antigen; D: IFN-γ treated cells stained for ICAM-1 (magnification ×400).

cytic infiltration, but lymphocytes were seen in sections from all of the tumours. The “normal” tissue taken from these patients showed no evidence of tumour cell infiltration. Microscopic examination of the samples of tissue obtained from six patients with ulcerative colitis showed the typical features of ulcerative colitis with severe inflammation, associated with a heavy inflammatory cell infiltrate, crypt abscess formation and some epithelial dysplasia. None of these specimens showed any evidence of malignancy.

**Expression of MHC antigens and ICAM-1 by tumours and other tissues**

The constitutive MHC and ICAM-1 expression by the original tumours was investigated in tissue sections. Staining of tumour sections for MHC class I antigens showed these to be present in all three cases in which staining was absent either completely or in parts of the tumour. However, staining with the anti-class II antibodies showed that in no case was there general or even extensive expression by the malignant glandular epithelium cells, although vascular endothelium, infiltrating inflammatory cells and Peyer’s patches all stained strongly within the same section. In occasional tumours a few of the malignant cells stained weakly. This was a surprising result: there have been several previous reports that colorectal tumours express MHC class II antigens and in a series
of 50 we expected several positive results. On the other hand, in four samples the “normal” colonic mucosa derived from regions of the colon close to the tumour exhibited class II staining of the epithelial cells. Also, all of the tissue samples from all six cases of ulcerative colitis expressed class II antigens. In all of these cases a leucocytic infiltrate was present. Similarly, malignant mucosal cells did not stain for ICAM-1 in any of the sections although again vascular endothelium, infiltrating inflammatory cells and Peyer’s patches all stained clearly. The ICAM-1 “normal” bowel positive for class II antigens, were also ICAM-1 positive, as were the samples from patients with ulcerative colitis.

**SHORT TERM CULTURES OF TUMOUR CELLS**

Cells in suspension cultures derived from 40 of the 50 tumours remained more than 65% viable for a minimum of 72 hours as assessed by trypan blue exclusion. The remaining cultures were lost either to microbial contamination or rapid decline in cell viability. Stained cytospin preparations of the cultures demonstrated the presence of viable tumour cells, which could be confidently distinguished from leucocytes or fibroblasts as judged on morphological criteria (fig 1). Staining with antibodies to CEA or cyto keratin was also used to confirm the presence of carcinoma cells in the culture.

With most of the cultures, significant numbers of viable tumour cells persisted for many days and in some cases tumour spheroids formed. However, no attempt was made to establish growing cultures or indeed to maintain the cultures beyond the experimental period.

**INDUCTION OF MHC ANTIGENS AND ICAM-1 IN CULTURED TUMOUR CELLS**

There was no change in expression of class II antigens (fig 1A) or ICAM-1 (fig 1B) by tumour cells in the control cultures untreated with IFN-γ; in all cases tumour cells were negative for both class II antigens (staining with both Serotec and Dako antibodies) and ICAM-1 and positive for MHC class I antigens, confirming the results obtained with the tumour sections. On the other hand, in eight of the IFN-γ treated cultures (20%) there was clear staining for both class II antigens (fig 1C) and ICAM-1 (fig 1D) in cells which were identifiable as tumour cells on morphological grounds, indicating that these molecules were induced in the tumour cells. The proportion of cells expressing these antigens varied between 50 and 90% in cultures from different tumours. Expression was apparent by 24 hours and persisted for at least 72 hours: however, by one week all tumour cells in the culture were negative. In some cases (five of eight) it was possible to re-treat inducible cultures and both MHC class II antigen and ICAM-1 expression could be induced for a second time. Cells from seven adenomas were similarly cultured and treated: no induction of class II antigens or ICAM-1 was detected.

Inducible cultures were derived pre-

dominantly (six of eight) from moderately differentiated Dukes’ stage B carcinomas; the others were a well differentiated Dukes’ stage A and a moderately differentiated Dukes’ stage C tumour. The degree of inflammatory infiltrate as seen by conventional haematoxylin and eosin staining and confirmed by CD3 and interleukin-2 receptor staining on the tissue sections did not appear to be related to the inducibility of MHC class II antigen and ICAM-1 expression. In cases where the “normal” mucosa expressed MHC class II antigens and ICAM-1 none of the tumour cells could be induced to express either molecule. Although the follow up time was short (12–24 months) five patients have died of their disease, but these patients did not have tumour cells capable of expressing MHC class II antigens or ICAM-1.

In some cases attempts were made to induce MHC class II antigens and ICAM-1 with retinoic acid on TNF-α, but these were uniformly unsuccessful.

**Discussion**

Previous studies have reported that MHC class II antigens are expressed by the colonic mucosa in colorectal tumours and in some cases have been associated with the presence of infiltrating mononuclear leucocytes. Whether or not the MHC class II or ICAM-1 phenotype influences prognosis is the subject of continued debate and there are conflicting series of follow up data. A series reported by Möller et al in 1991 did not find any supportive evidence for MHC class II antigen expression influencing the outcome of the disease, but a more recent publication by Norheim-Andersen et al appeared to suggest that the presence of MHC class II antigen expression may be correlated with a more favourable prognosis as seen in gastric cancer, squamous carcinoma of the larynx and breast cancer.

In the 50 carcinomas studied here very limited constitutive MHC class II antigen expression was found, despite the presence of activated inflammatory cells in all the tumours, and heavy infiltration in six. The result was confirmed by restaining the whole series with a second and a third antibody to MHC class II antigens, one of which had been used in a previous series to stain MHC class II antigens in colorectal tumours. In all cases it was clear that inflammatory and other non-malignant cells within the tumour stained, thus acting as an internal control. We observed both MHC class II antigen and ICAM-1 expression in areas of “normal” mucosa adjacent to tumours and in samples of ulcerative colitis. The ulcerative colitis samples were used as a positive control, an inflammatory condition without malignancy. Also, in a series of oesophageal carcinomas stained in parallel, some six of 37 tumours clearly stained strongly with the Dako CR3/43 antibody. We are therefore confident that in the tumours studied here there was little or no expression of MHC class II antigens by the malignant cells.

Similarly, we found little or no ICAM-1
expression. There is little documented with regard to the expression of ICAM-1 in colorectal cancer. In a study by Kelly et al. constitutive expression was described in five of 10 cancers. However, positively staining cells were infrequent, and amounted to less than 5% of the epithelial cells in any given section. The authors considered this expression to be more prevalent in areas of lymphocytic infiltration.

The main purpose of this study was to determine whether these antigens were inducible in ex vivo tumour cells and so non-expressing tumours were the essential starting material. We found that in cultures from at least some of the tumours (20%), both MHC class II antigen and ICAM-1 expression was inducible in the malignant cells. The expression was coordinately induced in that in tumours where MHC class II antigen expression was induced, so was ICAM-1. However, no double staining was done so we do not know whether both antigens were coordinately expressed in individual cells: this is likely in those cultures where most cells were expressing these antigens. The failure of the induction of MHC class II antigens and ICAM-1 in the cultures of the remaining tumours could potentially be due to technical reasons, such as low viability, but there were no obvious differences in viability between these cultures and the responding cultures, nor where there obvious differences in the morphology of the tumour cells, frequency of other cell types present, etc. The ability of the tumour cells to respond in vitro to IFN-γ treatment was independent of the degree of differentiation, stage of the cancer, or the degree of inflammatory infiltration of the original tumour. We feel it is a reasonable conclusion that in some colorectal carcinomas which do not express MHC class II antigens or ICAM-1 in vivo these antigens can be induced at least by IFN-γ but that the majority are not inducible.

In the inductive tumours the lack of in vivo expression was presumably due to the lack of sufficient local cytokine production, or production of inhibitory factors. In these tumours activated T cells (positive for CD25, the interleukin-2 receptor) and macrophages were seen in all the sections examined but it cannot be assumed that they are capable of producing physiological amounts of pro-inflammatory cytokines to augment ICAM-1 and MHC class II antigen expression, although we have found that tumour infiltrating lymphocytes are capable of producing similar amounts of IFN-γ to peripheral blood cells from the same patient. Failure of tumour cells to respond to IFN-γ could be because of—for example, lack of appropriate receptors, or the presence of inhibitory factors such as TGF-β produced by cancer cells and dampening any response. Many established colon cancer lines treated with cytokines retain the ability to respond to stimulation with the upregulation of ICAM-1 expression to a greater or lesser degree50 (and our own unpublished observations which indicate that seven of nine lines respond to IFN-γ by expressing MHC class II antigens and ICAM-1). We found that two primary colorectal tumour lines, after being maintained in vitro for a few weeks, expressed HLA-DR in response to IFN-γ to a greater degree. These observations would tend to support the hypothesis that local factors within the tumour environment limit the responsiveness of the tumour cells to cytokines, and this hyporesponsiveness may permit the tumour cells to escape both non-MHC restricted and MHC restricted lymphocyte killing, and in doing so confer a growth and metastatic advantage. This may have implications when deciding whether adjuvant therapy, possibly with cytokines, should be offered to these patients.

We are grateful to the Cancer Research Campaign for financial support.

Activation of ICAM-1 and MHC class II antigens by IFN-γ


Activation by interferon-γ of expression of ICAM-1 and MHC class II antigens in tumour cells from colorectal carcinomas

I Donnellan, J Cantrill, I Fraser and A Morris

_Clin Mol Pathol_ 1995 48: M40-M45
doi: 10.1136/mp.48.1.M40

Updated information and services can be found at:
_http://mp.bmj.com/content/48/1/M40_

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
_http://group.bmj.com/group/rights-licensing/permissions_

To order reprints go to:
_http://journals.bmj.com/cgi/reprintform_

To subscribe to BMJ go to:
_http://group.bmj.com/subscribe/_